Management of Cardiovascular Valvular Disease States

Introduction to Valvular Heart Disease

The European Society of Cardiology recommends a systematic approach to managing valvular heart disease, based on valve-specific pathophysiology, with intervention timing guided by symptoms, ventricular function, and hemodynamic severity, prioritizing early intervention before irreversible cardiac damage occurs 1, 2

The European Heart Association notes that aortic stenosis is characterized by a harsh systolic ejection murmur at the right upper sternal border radiating to carotids, with diminished or absent S2 in severe cases 3
The American College of Cardiology recommends that asymptomatic patients with severe AS require regular monitoring with echocardiography every 6-12 months 3
Intervention is indicated for symptomatic severe AS, asymptomatic severe AS with LV dysfunction, or severe AS in patients undergoing CABG or other cardiac surgery 4

The European Heart Association states that chronic AR has a prolonged compensated phase with gradual LV dilation, with a rate of progression to symptoms or LV dysfunction of approximately 4-6% per year 5
The American Heart Association recommends regular echocardiographic monitoring every 1-2 years for moderate AR, and medical therapy with vasodilators for symptomatic improvement 5
Surgical intervention is indicated for symptomatic severe AR, asymptomatic severe AR with LV dysfunction, or severe AR with aortic root dilation ≥50mm 1, 5

The European Society of Cardiology notes that mitral stenosis is characterized by a loud S1, opening snap, and diastolic rumble at the apex, with signs of pulmonary hypertension and right heart failure in advanced cases 3
The American College of Cardiology recommends medical therapy with heart rate control and anticoagulation for patients with atrial fibrillation or prior embolism, and intervention for symptomatic moderate-to-severe MS 6

The European Heart Association states that primary MR is progressive with a risk of LV dysfunction over time, while secondary MR has a prognosis tied to underlying ventricular disease 1
The American Heart Association recommends surgical repair for primary MR when feasible, and intervention for symptomatic severe MR or asymptomatic severe MR with LV dysfunction or dilation 1

The European Society of Cardiology notes that tricuspid regurgitation is characterized by a holosystolic murmur at the left lower sternal border that increases with inspiration, with signs of right heart failure 7
The American College of Cardiology recommends medical therapy with diuretics for symptom relief, and surgical intervention for severe TR in patients undergoing left-sided valve surgery or with symptomatic severe primary TR 2, 8

The European Heart Association recommends that when either stenosis or regurgitation is predominant, follow recommendations for the predominant lesion, and consider interactions between valve lesions 1
The American Heart Association notes that patients with combined valve disease may develop symptoms earlier than those with isolated lesions, and decision for multiple valve intervention must account for increased surgical risk 1, 5